| Aggressive Non-Hodgkin Lymphoma studied in …STUDIED_INderived200 of 648show all (up to 200) |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01676805recruiting Tissue Collection for Studies of Lymph Cancer · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561048Phase 3 · recruiting Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04414163Phase 2 · active not recruiting A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04301076Phase 1 · recruiting Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Acute Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06395103Phase 1/Phase 2 · recruiting Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06137144Phase 1/Phase 2 · recruiting AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06724237Phase 3 · recruiting Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819396Phase 2 · not yet recruiting Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01318317Phase 1/Phase 2 · active not recruiting Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01849263Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393738Phase 1 · recruiting A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04803201Phase 2 · recruiting Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01961063Phase 1 · active not recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | AIDS-Related Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04315324Phase 1/Phase 2 · active not recruiting Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07432022Phase 1/Phase 2 · recruiting A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784726Phase 2 · recruiting Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791615Phase 2 · not yet recruiting A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma · condition mapped PROBABILISTIC · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06442475Phase 2 · recruiting Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07388563Phase 1 · suspended Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959085Phase 3 · recruiting Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389423Phase 1 · recruiting Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07055477Phase 1 · recruiting A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404088Phase 2 · active not recruiting Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05254899Phase 2 · completed A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00336063Phase 1 · active not recruiting Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02223208Phase 1/Phase 2 · completed Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06710418NA · recruiting Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06927466Phase 1 · recruiting A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07735533Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768943Phase 2 · not yet recruiting GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07662928Phase 2 · not yet recruiting Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649304Phase 1 · not yet recruiting AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | AIDS-Related Diffuse Large B-cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07678229Phase 3 · recruiting BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07727083recruiting Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06340737Phase 1 · recruiting AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07758673Phase 1 · not yet recruiting Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03136146Phase 2 · recruiting Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Adult Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03504644Phase 1/Phase 2 · active not recruiting Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Adult Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03656835NA · active not recruiting Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05990465Phase 1 · recruiting LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533579Phase 1/Phase 2 · recruiting Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06600568recruiting Novel Therapeutic Approach for Human T-cell Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07750886recruiting Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02443077Phase 3 · active not recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069699Phase 1/Phase 2 · recruiting Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02981628Phase 2 · active not recruiting Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914625Phase 3 · active not recruiting A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07072585Phase 2/Phase 3 · not yet recruiting Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03264131Phase 2 · completed BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377827Phase 1 · suspended Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04703192Phase 2 · active not recruiting Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06471738Phase 2 · recruiting Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00501826Phase 2 · recruiting Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01371630Phase 1/Phase 2 · recruiting Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Large B-Cell Lymphoma with 11q Aberration | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077527Phase 1 · recruiting Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | AIDS-Related Diffuse Large B-cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05303792Phase 2 · active not recruiting Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07691450Phase 1 · not yet recruiting Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Enteropathy-Associated T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03269669Phase 2 · active not recruiting Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03810196NA · recruiting CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05805605Phase 2 · recruiting Allo HSCT Using RIC and PTCy for Hematological Diseases · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07678307Phase 1/Phase 2 · not yet recruiting A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05653271Phase 1 · completed ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520791Phase 1 · active not recruiting Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205409Phase 2 · completed Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03314974Phase 2 · recruiting Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00408005Phase 3 · completed Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04545762Phase 1 · recruiting Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502768Phase 1/Phase 2 · recruiting Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07657494NA · recruiting Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05475925Phase 1/Phase 2 · recruiting A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Primary Cutaneous Gamma-Delta T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01787409NA · active not recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02232516Phase 2 · completed Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03017820Phase 1 · recruiting A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637929not yet recruiting Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07639879Phase 3 · not yet recruiting TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma · condition mapped PROBABILISTIC · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07278856Phase 1 · recruiting Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06131801recruiting Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948786Phase 2 · recruiting Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07555431Phase 2 · recruiting Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739813Phase 1 · active not recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412290Phase 1 · active not recruiting Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04195633Phase 2 · recruiting Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01190930Phase 3 · completed Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05700448Phase 3 · not yet recruiting Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598998Phase 1/Phase 2 · active not recruiting Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05480449Phase 1/Phase 2 · recruiting Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) · condition mapped PROBABILISTIC · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01962636NA · terminated Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02877303Phase 2 · recruiting Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05978141recruiting A Registry for People With T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02797470Phase 1/Phase 2 · active not recruiting Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03246906Phase 2 · terminated Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02362035Phase 1/Phase 2 · completed ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05794880NA · recruiting MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06014762Phase 1 · active not recruiting P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03035331Phase 1/Phase 2 · completed Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01231412Phase 3 · completed Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07075328Phase 1/Phase 2 · recruiting A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554482Phase 2 · not yet recruiting Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03593018Phase 3 · completed Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097363Phase 2 · recruiting Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545603Phase 2 · recruiting Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020678Phase 1 · active not recruiting NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01384513Phase 2 · completed A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491370Phase 1/Phase 2 · recruiting Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07356245Phase 2 · recruiting Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476105NA · not yet recruiting Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544265Phase 1 · recruiting SynKIR-310 for Relapsed/Refractory B-NHL · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04450173Phase 2 · active not recruiting Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07523555Phase 1/Phase 2 · recruiting Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07525466Phase 1/Phase 2 · recruiting Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404660Phase 1/Phase 2 · active not recruiting A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04488354Phase 1 · completed Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04417166Phase 2 · active not recruiting Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692452Phase 2 · withdrawn Tazemetostat Plus CHOP in 1L T-cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04088890Phase 1 · completed Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05674175Phase 1/Phase 2 · recruiting Co-administration of CART22-65s and huCART19 for B-ALL · condition mapped PROBABILISTIC · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476027early Phase 1 · not yet recruiting Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03590574Phase 1/Phase 2 · terminated Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026319Phase 1 · recruiting CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02737046Phase 2 · completed Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03458260Phase 2 · completed Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446457Phase 2 · active not recruiting Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07457177Phase 2 · not yet recruiting Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06698003Phase 2 · recruiting A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04425421recruiting Recommendations for the Treatment of Children With Burkitt's Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05755087Phase 1 · recruiting Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04362007Phase 1/Phase 2 · terminated A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05170828Phase 1 · withdrawn Cryopreserved MMUD BM With PTCy for Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04512716early Phase 1 · recruiting Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04690595Phase 1 · active not recruiting BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04848064Phase 1 · recruiting Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883437Phase 2 · recruiting Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03749018Phase 2 · active not recruiting Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07385989Phase 2 · not yet recruiting Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633615Phase 2 · recruiting Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04285268Phase 2 · withdrawn Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583149Phase 2 · active not recruiting Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834373Phase 2 · recruiting Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06069830NA · recruiting PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06575686Phase 2 · suspended Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03210662Phase 2 · completed Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03278782Phase 1/Phase 2 · active not recruiting Study of Pembrolizumab (MK-3475) in Combination With Romidepsin · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05464329Phase 1 · active not recruiting Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03674411Phase 2 · active not recruiting Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05260957Phase 2 · recruiting CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05336409Phase 1 · terminated A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191187Phase 2 · completed Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07276698Phase 2 · not yet recruiting Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07276737Phase 2 · not yet recruiting Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06485076NA · recruiting Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568553Phase 1 · completed Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01286272Phase 2 · completed Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02588651Phase 2 · completed A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02337985Phase 1 · active not recruiting Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | AIDS-Related Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02996773Phase 1 · completed Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03375619recruiting Long-term Follow-up Study of Patients Receiving CAR-T Cells · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00776373Phase 1/Phase 2 · terminated Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies · condition mapped ALIAS · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05031897Phase 2 · recruiting Two Step Haplo With Radiation Conditioning · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890352Phase 2 · recruiting Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05565417Phase 1/Phase 2 · active not recruiting Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05270057Phase 1 · active not recruiting Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies · condition mapped ONTOLOGY_EXACT · 648 trials mapped (198 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |